Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  10.00 1.27% 800.00 3,658,821 16:11:20
Bid Price Offer Price High Price Low Price Open Price
790.00 810.00 800.00 790.00 795.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 68.26 4.99 12.00 66.7 387
Last Trade Time Trade Type Trade Size Trade Price Currency
17:53:49 O 3,400 787.437 GBX

Ergomed (ERGO) Latest News

More Ergomed News
Ergomed Takeover Rumours

Ergomed (ERGO) Discussions and Chat

Ergomed Forums and Chat

Date Time Title Posts
25/9/202019:37Ergomed PLC733
14/1/202010:16Stephen Stamp, CFO of Ergomed (ERGO)2

Add a New Thread

Ergomed (ERGO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ergomed trades in real-time

Ergomed (ERGO) Top Chat Posts

Ergomed Daily Update: Ergomed Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ERGO. The last closing price for Ergomed was 790p.
Ergomed Plc has a 4 week average price of 610p and a 12 week average price of 475p.
The 1 year high share price is 800p while the 1 year low share price is currently 260p.
There are currently 48,411,442 shares in issue and the average daily traded volume is 216,118 shares. The market capitalisation of Ergomed Plc is £387,291,536.
grabster: Reported in Shares magazine this afternoon: Market & Company News: Ergomed profit up 44% as Covid-related trials boost business 22 September 2020, 14:03Source - SMW Pharmaceutical services company Ergomed posted a 44% rise in first-half profit after it won new business, including in Covid-19-related trials, and substantially boosted revenue in North America. The company also said it was planning a capital reduction, in light of its financial progress 'and to increase its ability to pay dividends, to facilitate any prospective buy back of shares and for any other general corporate purposes'. Pre-tax profit for the six months through June increased to £6.0m, up from £4.1m on-year, as revenue climbed 15% to £40.4m, including by 79% in North America. The company did not declare an interim dividend. 'Ergomed has delivered exceptional progress both operationally and financially during the first half of 2020, continuing to demonstrate our ability to drive sustained growth through a clear focus on our service model strategy,' chief executive Miroslav Reljanovic said. 'We responded robustly to the challenges of the Covid-19 pandemic, with strong revenue and profit growth, a growing order book and sales momentum across the business.' 'We expect to see this momentum continue into the second half of the year, driven by further demand for our PV and CRO services.' 'We will continue to invest for organic growth and efficiency with a disciplined approach to strategic acquisition opportunities and are firmly positioned to realise our potential as a leading global provider of specialist services to the pharmaceutical industry.' At 2:03pm: (LON:ERGO) Ergomed Plc share price was +85p at 775p
tongosti: I think so but more importantly the share price shares our thoughts too.
firtashia: Despite being “materially221; ahead of expectations, it would appear that ERGO’s EPS forecasts for FY20 have been raised by only 6%. This would seem far too conservative & presents further opportunity for upgrades as the year progresses, hopefully acting as a fillip for the share price.
firtashia: good to see you here tongosti, when the interests of traders and investors align hopefully good things will happen to the share price :-)
firtashia: Nimbo1- Just noticed forward Eps estimates have been revised upwards-might be the reason for the recent share price movement.
nimbo1: thanks. wow I like the zebra's - no wonder the share price is going up.
mfhmfh: great company... share price back to 330p soon. IMHO.
timbo003: I had assumed that the recent perkiness in the Ergo share price was due to them shifting away from the co-development model and just focusing on the pharmaceutical services parts of the business. Unfortunately I couldn't get to the AGM earlier this year, if I had gone, I had lots of questions about that. If they end up making the transition completely, I wonder if they are contemplating selling the future royalty streams from the current co-development portfolio? I suspect there would be plenty of potential buyers.
epicsurf: Been watching cel-sci share price up around 10% today . Ergomed is a new share purchase for me In at £2.34 so happy with uptick
jamtomorrow2: Interesting that Cel-Sci’s share price has doubled recently on optimism that Multikine’s trial will be successful. Ergomed has an interest in this drug.
Ergomed share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200927 04:59:58